bronchitis%20-%20chronic%20in%20acute%20exacerbation
BRONCHITIS - CHRONIC IN ACUTE EXACERBATION

Chronic bronchitis is an infection of the trachea and bronchi for at least 3 consecutive months for more than 2 consecutive years.
The patient experiences symptoms of increase in dyspnea, sputum volume and sputum purulence over baseline on most days.

Diagnosis is basically based on clinical presentation.

Definition

  • Chronic bronchitis is a clinical diagnosis of sputum expectoration on most days during at least 3 consecutive months for more than 2 consecutive years

Signs and Symptoms

  • Symptoms of exacerbation are increase in dyspnea, sputum volume & sputum purulence over baseline

Risk Factors

Risk Factors for Exacerbations

  • Tracheobronchial infections (eg influenza, streptococcal infection)
  • Environmental exposures (eg air pollution)
  • Noncompliance w/ O2 therapy or pulmonary rehabilitation program
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
one year ago
Tiotropium Respimat is superior over Handihaler in improving time of sleep spent with sleeping oxygen saturation below 90 (TST90) and sleep parameters in patients with chronic obstructive pulmonary disease (COPD) as performed in a randomised, open-label, parallel group trial.
Pearl Toh, one year ago
Workers at cement plants who were exposed to high levels of cement dust saw their lung function declined at a faster rate than those less exposed, according to a recent study.
one year ago
Beclomethasone and formoterol combination pressurised metered-dose inhaler is effective for long-term asthma management, as revealed in the CASPER noninterventional, observational trial in Poland.
Naomi Rodrig, 2 years ago
The BRAF inhibitors vemurafenib and dabrafenib, currently approved for use in advanced melanoma, are also effective in a subset of lung adenocarcinoma patients with BRAF mutations, according to a retrospective European trial presented at the European Lung Cancer Conference (ELCC) held in Geneva, Switzerland.